EurekAlert!

Can adrenaline auto-injectors prevent fatal anaphylaxis?

Individuals at risk of anaphylaxis—an acute systemic hypersensitivity reaction to an allergen or trigger, typically associated with skin reactions, nausea/vomiting, difficulty breathing, and shock—are ...
WREX

'Dillon's Law' to expand access to epinephrine unanimously passed by Illinois Assembly

SPRINGFIELD, Ill. (WREX) — A bill allowing more people to give life-saving medication to those having severe allergic reactions has passed through the Illinois General Assembly. Lawmakers in ...
Healio

Epinephrine nasal spray recommended for approval in European Union

Please provide your email address to receive an email when new articles are posted on . The recommendation was based on data from more than 700 study participants. European Commission authorization is ...
Seeking Alpha

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 ...
Nasdaq

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to ...
HTR Media

Mishicot family continues fight in expanding epinephrine access as Congress debates 'Dillon's Law'

MANITOWOC - While Wisconsin has done the work to increase access to epinephrine statewide through laws named after Angel Mueller's son, Mueller is now pushing to see the entire nation increase access ...
Nasdaq

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales ARS Pharma is also evaluating its intranasal ...